How to Safely Stop Finasteride: An Evidence-Based Discontinuation Guide

Editorial evidence status: Rebuilt from current U.S. labeling, the 2026 MHRA safety update, and discontinuation studies on August 29, 2026. A licensed clinician has not approved this revision. It remains in Medical/expert approval required status.

First identify which finasteride decision you are making

The 1 mg and 5 mg tablets contain the same drug but support different treatment goals. Treating them as one discontinuation problem creates bad advice.

The correct plan is therefore not a step-down calendar. It is an indication-specific handoff.

Does finasteride need to be tapered?

Current U.S. prescribing information does not require a taper. In healthy volunteers treated for 14 days, the 5 mg label reports that serum dihydrotestosterone (DHT) returned to pretreatment levels in approximately two weeks after discontinuation. That is a pharmacodynamic observation, not evidence that alternate-day dosing improves hair retention, prevents symptoms, or changes long-term outcomes.

The old version of this page supplied an eight-week taper with estimated DHT percentages. No cited randomized discontinuation trial validated that schedule. It also implied that tapering would help the hormonal axis “recalibrate,” even though the label reports no effect on the hypothalamic-pituitary-testicular axis in healthy volunteers. Those claims have been removed.

A clinician may still sequence changes for practical reasons—for example, so that only one medicine changes at a time. That is a case-management choice, not a physiological requirement to wean finasteride.

What the hair-loss evidence actually shows after stopping 1 mg

The clearest discontinuation result is in the U.S. 1 mg label. Men in the vertex-hair studies who took finasteride for the first 12 months and then switched to placebo lost the increase in hair count 12 months later. The label also says continued use is recommended to sustain benefit and that withdrawal leads to reversal of effect within 12 months.

That finding supports a broad expectation: hair preserved or gained because of finasteride is not permanently locked in after the drug stops. It does not establish that every person will start shedding at month three, return to a specific Norwood stage, or lose all benefit on an identical schedule. Hair-cycle timing, baseline progression, measurement method, and other treatments vary.

A reproducible way to judge the change

If appearance is the reason for the decision, make the comparison less vulnerable to memory:

1. Photograph the frontal, mid-scalp, and vertex views before the change.
2. Use the same room, light direction, camera distance, hairstyle, and wet/dry state each time.
3. Record every concurrent hair treatment and its start or stop date.
4. Compare at spaced intervals rather than reacting to day-to-day shed counts.
5. Ask whether the observed change alters the treatment goal, not merely whether two photographs look different.

This record cannot prove which medicine caused a change. It can prevent lighting and styling differences from masquerading as treatment response.

Why stopping 5 mg for BPH is a different safety decision

Current finasteride 5 mg labeling indicates the medicine for symptomatic BPH in men with an enlarged prostate and states that it reduces the risk of acute urinary retention and BPH-related surgery [2]. That labeled population and outcome boundary should not be expanded into a universal stopping rule.

Withdrawal does not create a classic drug-withdrawal syndrome, but it can remove those disease-management effects. In a prospective study of 120 men who received a 5-alpha-reductase inhibitor plus an alpha blocker for a year and then continued the alpha blocker alone, prostate volume increased and symptom scores worsened during the following year. The study included both finasteride and dutasteride groups, used a specific combination-therapy population, and does not predict one person's timing.

Call promptly for inability to urinate, severe lower-abdominal pain with bladder fullness, fever with urinary symptoms, or visible blood in the urine. Those problems require assessment regardless of whether finasteride was recently stopped.

Record finasteride exposure before interpreting PSA

Finasteride lowers PSA during treatment. The current 5 mg label says to establish a new PSA baseline after six months and to double an isolated PSA value in patients treated for six months or more when comparing it with normal ranges in untreated men [2]. That is not a universal post-discontinuation calendar. After stopping, recovery of PSA can reflect changing drug effect, prostate biology, inflammation, or another condition.

Do not silently apply a “multiply by two for six months” rule to your own result. Give the ordering clinician:

• the 1 mg or 5 mg dose;
• the treatment start and stop dates;
• the reason it was prescribed;
• prior PSA results and whether they were obtained before, during, or after therapy; and
• any new urinary symptoms, infection, procedure, or ejaculation near the test that the clinician asks about.

That timeline is more useful than a correction factor detached from the case.

Side effects after stopping: separate the warning from the prediction

Finasteride labels and regulators recognize sexual adverse effects, and current UK guidance says sexual dysfunction may persist after treatment is stopped. The May 2026 MHRA update also associates finasteride with depression and suicidal ideation. It advises people taking 1 mg for hair loss to stop and contact a healthcare professional as soon as possible if depression or suicidal thoughts develop; people taking 5 mg for BPH are advised to contact a healthcare professional as soon as possible. Anyone at immediate risk of self-harm needs emergency help where they live.

The MHRA's May 2026 safety update uses careful association language: “finasteride is associated with depression, suicidal ideation and sexual dysfunction which may persist after treatment is stopped” [3]. The wording is exact from “Advice for Healthcare Professionals,” first bullet. The issuing body is the UK medicines regulator; this short excerpt records its warning and does not establish causation, a recovery timetable, or endorsement of this page.

These warnings establish that persistent symptoms have been reported and deserve care. They do not establish a percentage who will recover by week four, prove one mechanism for every persistent symptom, or create a single laboratory panel. The prior page's promise that most sexual symptoms resolve within one to four weeks and its automatic endocrine panel were not supported by the cited evidence.

For a clinical visit, record symptom onset, dose, last dose date, other medicines, mood changes, sexual-function changes, sleep, substance use, and relevant health events. That does not prejudge causality; it makes alternative explanations and time relationships easier to assess.

A one-page discontinuation record

This artifact is a record, not a dosing protocol. Its purpose is to preserve the facts that are usually lost when treatment changes.